Medical need, scientific opportunity and the drive for antimalarial drugs

Nature

Volumn 415, Issue 6872, 2002, Pages 686-693

  Ridley, Robert G ^a  

^a Medicines for Malaria Venture   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; DRUG PRODUCTS; ECONOMIC AND SOCIAL EFFECTS; HEALTH CARE; SUSTAINABLE DEVELOPMENT;

POVERTY;

MALARIA CONTROL;

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEETHER; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; FANSIDAR; HALOFANTRINE; MEFLOQUINE; QUININE;

DISEASE CONTROL; DRUG DEVELOPMENT; MALARIA; SOCIOECONOMIC CONDITIONS;

DRUG COST; DRUG INDUCED DISEASE; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; HEALTH CARE COST; HUMAN; MALARIA; MALARIA CONTROL; POVERTY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIMALARIALS; HEALTH SERVICES ACCESSIBILITY; HUMANS; NEEDS ASSESSMENT; PLASMODIUM; RESEARCH;

CINCHONA PUBESCENS; PROTOZOA;

EID: 0037034009     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/415686a     Document Type: Review

References (98)

1. Thalidomide: Current and potential clinical applications
2. Chloroquine-resistant malaria
3. Dihydrofolate reductase and antifolate resistance in malaria
4. Quinoline anti-malarials
5. 4-Aminoquinolines - Past, present, and future: A chemical perspective
6. How chinese scientists discovered qinghaosu (artemisinin) and developed its derivatives. What are the future perspectives?
7. Artemisinin drugs: Novel antimalarial agents
8. Artemisinin and derivatives: The future for malaria treatment?
9. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo
10. Delaying antimalarial drug resistance with combination chemotherapy
11. Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine
12. Combination therapy for malaria in Africa: Hype or hope?
13. Arteether-induced brain injury in Macaca mulatta. I. The precerebellar nuclei: The lateral reticular nuclei, paramedian reticular nuclei, and perihypoglossal nuclei
14. Neurotoxicity and artemisinin compounds. Do the observations in animals justify limitation of clinical use?
15. Clinical and neurophysiological study of the effects of multiple doses of artemisinin on brain-stem function in Vietnamese patients
16. Severe allergic reactions to oral artesunate: A report of two cases
17. Positioning, labelling, and medical information control of coartemether tablets (CPG 56697): A fixed novel combination of artemether and benflumetol
18. Desbutylbenflumetol, a novel antimalarial compound: In vitro activity in fresh isolates of Plasmodium falciparum from Thailand
19. In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon
20. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria
21. Cost-effectiveness of sulfadoxine-pyrimethamine for the prevention of malaria-associated low birth weight
22. Therapeutic efficacy of sulphadoxine/pyrimethamine and susceptibility in vitro of P. Falciparum isolates to sulphadoxine-pyremethamine and other antimalarial drugs in Malawian children
23. Drug resistance in malaria
24. Malarone (atovaquone and proguanil hydrochloride): A review of its clinical development for treatment of malaria. Malarone clinical trials study group
25. A plastid organelle as a drug target in apicomplexan parasites
26. Antimalarial drug development and new targets
27. Emerging targets for antimalarial drugs
28. A brief illustrated guide to the ultrastructure of Plasmodium falciparum asexual blood stages
29. Hemoglobin metabolism in the malaria parasite Plasmodium falciparum
30. Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets
31. Characterization of native and recombinant falcipain 2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum
32. Identification and characterisation of Falcilysin, a metallopeptidase involved in hemoglobin catabolism within the malarial parasite Plasmodium falciparum
33. The structure of malaria pigment βhaematin
34. Ferriprotoporphyrin IX fulfills the criteria for identification as the chloroquine receptor of malaria parasites
35. On the molecular mechanism of chloroquine's antimalarial action
36. Access to hematin: The basis of chloroquine resistance
37. Central role of hemoglobin degradation in mechanisms of action of 4-aminoquinolines, quinoline methanols, and phenanthrene methanols
38. A common mechanism for blockade of heme polymerization by antimalarial quinolines
39. Artemisinin and the antimalarial endoperoxides: From herbal remedy to targeted chemotherapy
40. Haematin (haem) polymerisation and its inhibition by quinoline antimalarials
41. The chemical basis for the ferriprotoporphyrin IX-chloroquine complex induced lipid peroxidation
42. Chloroquine - Some open questions on its antimalarial mode of action and resistance
43. Possible modes of action of the artemisinin-type compounds
44. Mutations in the P.falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance
45. Evidence for different mechanisms of chloroquine resistance in 2 Plasmodium species that cause human malaria
46. Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr 1 gene of Plasmodium falciparum
47. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum
48. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr 1 gene and cross-resistance to halofantrine and quinine
49. Hematin polymerization assay as a high-throughput screen for identification of new antimalarial pharmacophores
50. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil
51. A comparison of the phenomenology and genetics of multidrug resistance in cancer cells and quinoline resistance in Plasmodium falciparum
52. Enhanced efficacy of chloroquine-chlorpheniramine combination in acute uncomplicated falciparum malaria in children
53. Antimalarial peroxides in the qinghaosu (artemisinin) and yinghaosu families
54. Expert opinion on: Water soluble trioxanes as potent and safe antimalarial agents
55. Current progress in the chemistry, medicinal chemistry and drug design of artemisinin-based antimalarials
56. Peroxidic antimalarials
57. A plastid of probable green algal origin in Apicomplexan parasites
58. Complete gene map of the plastid-like DNA of the malaria parasite Plasmodium falciparum
59. Nuclear encoded proteins target the plastid in Toxoplasma gondii and Plasmodium falciparum
60. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum
61. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs
62. Peptidomimetic inhibnitors of protein farnesyltransferases show antimalarial activity
63. Mitochondria of mammalian Plasmodium spp.
64. Phenyl beta-methoxyacrylates: A new antimalarial pharmacophore
65. Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs
66. Chemotherapy for falciparum malaria: The armoury, the problems and the prospects
67. The antimalarial triazine WR99210 and the prodrug PS-15: Folate reversal of in vitro activity against Plasmodium falciparum and a non-antifolate mode of action of the prodrug
68. An overview of chemotherapeutic targets for antimalarial drug discovery
69. The structure of lactate dehydrogenase from Plasmodium falciparum reveals it new target for anti-malarial design
70. Intraerythrocytic Plasmodium falciparum expresses a high affinity facilitative hexose transporter
71. Membrane transport in the malaria-infected erythrocyte
72. A voltage-dependent channel involved in nutrient uptake by red blood cells infected with the malaria parasite
73. Proteases involved in erythrocyte invasion by the malaria parasite: Function and potential as drug targets
74. Transport of phospholipid synthesis precursors and lipid trafficking into malariainfected erythrocytes
75. An overview of Plasmodium protein kinases
76. Entering the post-genomic era of malaria research
77. The role of genomics in antibacterial target discovery
78. Advances in structural genomics
79. Transformation of Plasmodium falciparum malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine
80. Transfection of malaria parasites
81. Antimalarial drug discovery and development-an industrial perspective
82. Role of the development scientist in compound lead selection and optimization
83. Experimental and computational approaches to estimate solubility in drug discovery and development settings
84. Roll back malaria - What are the prospect?
85. A new global commitment to disease control in Africa